Inventor
MATSUSHIMA KOUJI
JP40 patents
⚠️ This page may combine multiple inventors who share the name “MATSUSHIMA KOUJI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CHUGAI PHARMACEUTICAL CO LTD
8 patentsUS6245894B1Jun 12, 2001
Reshaped human antibody to human interleukin-8
CHUGAI PHARMACEUTICAL CO LTD65 citations96
US6024956AFeb 15, 2000
Method to treat inflammation with humanized anti-IL-8-antibodies
CHUGAI PHARMACEUTICAL CO LTD59 citations96
US5994524ANov 30, 1999
Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
CHUGAI PHARMACEUTICAL CO LTD72 citations96
US5981486ANov 9, 1999
Peptide suppressing IκBα phosphorylation
CHUGAI PHARMACEUTICAL CO LTD36 citations90
US5707621AJan 13, 1998
Supression of nephritis-induced protein excretion by anti-IL-8
CHUGAI PHARMACEUTICAL CO LTD12 citations74
US6068840AMay 30, 2000
Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing CDRs or the variable region from the mouse monoclonal antibody, WS-4
CHUGAI PHARMACEUTICAL CO LTD11 citations73
US6048972AApr 11, 2000
Recombinant materials for producing humanized anti-IL-8 antibodies
CHUGAI PHARMACEUTICAL CO LTD6 citations73
US6497878B1Dec 24, 2002
Treatment of cerebral disorders by inhibition of IL-8 binding to receptor
CHUGAI PHARMACEUTICAL CO LTD5 citations54
UNIV TOKYO
6 patentsUS11572393B2Feb 7, 2023
HMGN partial peptide and cancer therapy using the same
UNIV TOKYO2 citations70
US10746726B2Aug 18, 2020
Method for assessing therapeutic effect of anti-cancer agent having anti-CD4 antibody as active ingredient
UNIV TOKYO1 citations61
US11919932B2Mar 5, 2024
HMGN partial peptide and cancer therapy using the same
UNIV TOKYO0 citations59
US11193172B2Dec 7, 2021
Method for predicting prognosis of patient with cancer or inflammatory disease
UNIV TOKYO0 citations50
US9895331B2Feb 20, 2018
Prophylactic and/or therapeutic agent for radiation damage
UNIV TOKYO0 citations41
US10722480B2Jul 28, 2020
Agent for controlling cells constituting cancer microenvironment or inflammatory microenvironment
UNIV TOKYO0 citations40
TELIK INC
5 patentsUS7297696B2Nov 20, 2007
Antagonists of MCP-1 function and methods of use thereof
TELIK INC18 citations91
US6670364B2Dec 30, 2003
Antagonists of MCP-1 function and methods of use thereof
TELIK INC14 citations82
US6809113B2Oct 26, 2004
Antagonists of MCP-1 function and methods of use thereof
TELIK INC8 citations72
US6677365B2Jan 13, 2004
Antagonists of MCP-1 function and methods of use thereof
TELIK INC11 citations72
US6992086B2Jan 31, 2006
Antagonists of MCP-1 function and methods of use thereof
TELIK INC1 citations51
US HEALTH
4 patentsUS5698196ADec 16, 1997
Antibodies specific for neutrophic chemotactic factor
US HEALTH58 citations95
US5925352AJul 20, 1999
Method of treating inflammation with antibodies to neutrophil chemotactic factor
US HEALTH12 citations81
US5652338AJul 29, 1997
Neutrophil chemotactic factor
US HEALTH15 citations81
US6475741B1Nov 5, 2002
Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto
US HEALTH0 citations51